Skip to main content

Table 3 Physiological end points by treatment group

From: The effect of polymyxin B hemoperfusion on modulation of human leukocyte antigen DR in severe sepsis patients

Outcome

PMX-HP group

Non-PMX-HP group

Baseline (n = 29)

Day 3 (n = 26)

P value within groupa

Baseline (n = 30)

Day 3 (n = 20)

P value within groupb

P value between groups on day 3c

P value between group change from baseline and day 3d

Primary outcome

 mHLA-DR expression (%), median (Q1, Q3)

33.4 (27.4–40.7)

39.2 (27.1–45.8)

0.025 e

30 (15.8–36.6)

30.7 (19.5–36.8)

0.13

0.027 (0.042) e

0.027 (0.11)e

 mHLA-DR expression (MFI), mean (SD)

481.4 (131.5)

509.0 (139.9)

0.78

446.6 (142.1)

447.3 (148.9)

0.35

0.16 (0.035)e

0.34 (0.038)e

Secondary outcomes

 CD11b (%), mean (SD)

15.4 (9)

13.7 (9.5)

0.30

14.3 (10.5)

16.2 (10.1)

0.001

0.39 (0.15)e

0.002 (0.001) e

 CD-11b (MFI), mean (SD)

189.7 (57.1)

165.4 (53.1)

0.045

186.2 (53.3)

223.5 (48.0)

< 0.001

0.001 (< 0.001) e

< 0.001 (< 0.001) e

 Neutrophil chemotaxis (%), mean (SD)

42.8 (12.5)

47.9 (10.2)

0.030

42.3 (13.7)

46.2 (12.3)

0.74

0.60 (0.77)e

0.07 (0.08)e

 Presepsin (pg/ml), median (Q1, Q3)

5514 (4088, 10,513)

2895 (2190, 6038)

0.059

5030 (2459, 10,734)

3468 (2204, 6038)

0.12

0.93

0.38

 CVS SOFA score, median (Q1, Q3)

4 (4, 4)

3 (0, 4)

0.003

4 (4, 4)

3 (1, 4)

0.26

0.71

0.16

 Inotropic score, median (Q1, Q3)

36 (6.6, 70)

11 (1, 49.2)

0.13

30 (2, 83)

14 (0, 36)

0.94

0.57

0.20

 Vasopressor dependency index (mmHg−1), median (Q1, Q3)

0.4 (0.1, 1.1)

0.1 (0.01, 0.7)

0.14

0.4 (0.1, 1.1)

0.2 (0, 0.6)

0.96

0.60

0.25

 Noradrenaline (μg/kg/min), median (Q1, Q3)

0.2 (0.0, 0.4)

0.01 (0, 0.2)

0.23

0.3 (0.0, 0.4)

0.1 (0, 0.4)

0.85

0.42

0.42

 EAA level, median (Q1, Q3)

0.8 (0.7, 1)

0.7 (0.6, 0.9)

0.11

0.7 (0.7, 0.9)

0.6 (0.5, 0.9)

0.14

0.84

0.90

  1. Data represent median (25th percentile, 75th percentile) unless otherwise noted
  2. PMX-HP polymyxin B hemoperfusion, mHLA-DR monocyte human leukocyte antigen, Q1 25th percentile, Q3 75th percentile, MFI mean fluorescence intensity, SD standard deviation, CVS SOFA cardiovascular Sequential Organ Failure Assessment, EAA endotoxin activity assay, Italic data represent P value statistically significant
  3. aP value for comparison between day 1 and day 3 within PMX-HP group using Student’s t test or Kruskal–Wallis test
  4. bP value for comparison between day 1 and day 3 within non-PMX-HP group using Student’s t test or Kruskal–Wallis test
  5. cP value for comparison between PMX-HP and non-PMX-HP groups on day 3 using Student’s t test or Kruskal–Wallis test
  6. dP value for comparing groups on mean or median change between day 3 and day 1 using Student’s t test or Kruskal–Wallis test
  7. eAdjusted for renal replacement therapy status
Back to article page

Critical Care

ISSN: 1364-8535